↓ Skip to main content

The rheumatoid arthritis treat-to-target trial: a cluster randomized trial within the Corrona rheumatology network

Overview of attention for article published in BMC Musculoskeletal Disorders, November 2014
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
12 Dimensions

Readers on

mendeley
39 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
The rheumatoid arthritis treat-to-target trial: a cluster randomized trial within the Corrona rheumatology network
Published in
BMC Musculoskeletal Disorders, November 2014
DOI 10.1186/1471-2474-15-389
Pubmed ID
Authors

Leslie R Harrold, George W Reed, J Timothy Harrington, Christine J Barr, Katherine C Saunders, Allan Gibofsky, Jeffrey D Greenberg, Ani John, Jenny Devenport, Joel M Kremer

Abstract

The treat-to-target (T2T) approach to the care of patients with rheumatoid arthritis involves using validated metrics to measure disease activity, frequent follow-up visits for patients with moderate to high disease activity, and escalation of therapy when patients have inadequate therapeutic response as assessed by standard disease activity scores. The study described is a newly launched cluster-randomized behavioral intervention to assess the feasibility and effectiveness of the T2T approach in US rheumatology practices. It is designed to identify patient and provider barriers to implementing T2T management. This initial paper focuses on the novel study design and methods created to provide these insights.Methods/design: This trial cluster-randomizes rheumatology practices from the existing Corrona network of private and academic sites rather than patients within sites or individual investigators to provide either T2T or usual care (UC) for qualified patients who meet the 2010 revised American College of Rheumatology criteria for the diagnosis of rheumatoid arthritis and have moderate to high disease activity. Specific medication choices are left to the investigator and patient, rather than being specified in the protocol. Enrollment is expected to be completed by the end of 2013, with 30 practices randomized and enrolling a minimum of 530 patients. During the 12-month follow-up, visits are mandated as frequently as monthly in patients with active disease in the T2T group and every 3 months for the UC group. Safety data are collected at each visit. The coprimary endpoints include a comparison of the proportion of patients achieving low disease activity in the T2T and UC groups and assessment of the feasibility of implementing T2T in rheumatology practices, specifically assessment of the rates of treatment acceleration, frequency of visits, time to next visit conditional on disease activity, and probability of acceleration conditional on disease activity in the 2 groups.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 39 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 39 100%

Demographic breakdown

Readers by professional status Count As %
Other 5 13%
Student > Bachelor 4 10%
Student > Ph. D. Student 4 10%
Researcher 4 10%
Student > Master 4 10%
Other 7 18%
Unknown 11 28%
Readers by discipline Count As %
Medicine and Dentistry 14 36%
Nursing and Health Professions 3 8%
Psychology 3 8%
Pharmacology, Toxicology and Pharmaceutical Science 2 5%
Agricultural and Biological Sciences 1 3%
Other 4 10%
Unknown 12 31%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 November 2014.
All research outputs
#18,385,510
of 22,772,779 outputs
Outputs from BMC Musculoskeletal Disorders
#3,125
of 4,039 outputs
Outputs of similar age
#261,780
of 361,837 outputs
Outputs of similar age from BMC Musculoskeletal Disorders
#76
of 90 outputs
Altmetric has tracked 22,772,779 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,039 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one is in the 10th percentile – i.e., 10% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 361,837 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 16th percentile – i.e., 16% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 90 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.